NDA 214783 · Sanofi-Aventis
Rezurock
Belumosudil Mesylate · Oral
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Jul 16, 2021: To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jul 16, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
3 Phase 3, 12 recruiting
FAERS reports
3,361
1,679 serious, 303 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2026.
REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. ( 1 )
Mechanism: Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 with IC 50 values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro -human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, in vitro . In vivo , belumosudil demonstrated activity in animal models of chronic GVHD.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 16, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- REZUROCK · BELUMOSUDIL MESYLATE EQ 200MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Belumosudil" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07771439 · 356 participants (planned) · Start Oct 12, 2026 · Primary completion Sep 14, 2029
Drug: Belumosudil · For: Chronic Graft Versus Host Disease
Sites: Amsterdam, Netherlands; Madrid, Spain · 3 sites in all
- A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06143891 · 260 participants (planned) · Start Jan 23, 2024 · Primary completion Sep 29, 2028
Drug: Belumosudil; Placebo and 2 more · For: Chronic Graft Versus Host Disease
Sites: Little Rock, Arkansas; Duarte, California; San Francisco, California · 151 sites in all
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
- Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsPivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06476132 · 234 participants (planned) · Start Mar 12, 2025 · Primary completion May 30, 2027
Drug: Belumosudil; Placebo for Belumosudil · For: Lung Transplant
Sites: Los Angeles, California; Palo Alto, California; Baltimore, Maryland · 12 sites in all
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft DysfunctionPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06082037 · 180 participants (planned) · Start Oct 10, 2023 · Primary completion Jan 29, 2029
Drug: Belumosudil; Azithromycin and 1 more · For: Lung Transplant Rejection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 85 sites in all
- Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHDPivotal-lookingRecruiting
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT07794514 · 170 participants (planned) · Start Oct 1, 2026 · Primary completion Apr 1, 2030
Drug: Ruxolitinib treatment; Belumosudil treatment and 2 more · For: Hematopoietic Stem Cell Transplantation (HSCT); cGVHD; Hepatic cGVHD and 2 more
Sites: Hangzhou, China
- Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyPivotal-lookingTerminated
Kadmon, a Sanofi CompanySanofi (SNY)
NCT03640481 · 159 participants · Start Oct 11, 2018 · Primary completion Dec 11, 2023
Drug: Belumosudil (KD025) · For: Chronic Graft-versus-host-disease
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 35 sites in all
- A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
Kadmon Corporation, LLCSanofi (SNY)
NCT02852967 · 110 participants · Start Sep 14, 2016 · Primary completion Feb 13, 2019
Drug: Belumosudil; Placebo · For: Chronic Plaque Psoriasis
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication484
- inappropriate schedule of product administration466
- fatigue273
- off label use240
- drug ineffective179
- pneumonia178
- death169
- nausea165
- product dose omission issue160
- diarrhoea151
- hospitalisation146
- condition aggravated145
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 73 |
| 2022 | 898 |
| 2023 | 290 |
| 2024 | 781 |
| 2025 | 732 |
| 2026 | 586 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rezurock (Belumosudil Mesylate)
2024 spending
$243M
Beneficiaries
1,371
10,182 claims
Per beneficiary
$177,193
$579.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $21,356,248 |
| 2022 | $100,434,804 |
| 2023 | $146,107,630 |
| 2024 | $242,932,266 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
Cutler C, Lee SJ, Arai S, et al. · Blood 2021 · Clinical Trial, Phase II, Multicenter Study
- ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
Jagasia M, Lazaryan A, Bachier CR, et al. · J Clin Oncol 2021 · Clinical Trial, Phase II, Multicenter Study
- Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis.
Rathje K, Gagelmann N, Heidenreich S, et al. · Transplant Cell Ther 2026 · Systematic Review, Meta-Analysis
- Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study.
Sharma R, Holtzman NG, Pusic I, et al. · Blood Adv 2025 · Clinical Trial, Phase II, Multicenter Study
- Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies.
Lee SJ, Pavletic S, Blazar BR, et al. · Transplant Cell Ther 2025 · Clinical Trial, Phase II, Multicenter Study
- An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.
Inamoto Y, Kato K, Kawakita T, et al. · Am J Hematol 2024 · Multicenter Study, Clinical Trial
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.